REVIEW ARTICLE Steven I. Hanish, Stuart J. Knechtle; ONCOLOGY Vol. 25 No. 8 In the future this modality may be able to be made available to patients whose disease does not meet the current Milan criteria while still providing them with acceptable long-term outcomes.
REVIEW ARTICLE Richard Kim, et al;ONCOLOGY Vol. 25 No. 3 Less is known about the effects of sorafenib in patients with decompensated liver disease, or of sorafenib in combination with local therapy or in a transplant setting. Prospective trials are lacking in these areas.
Assessing outcome after ablation is difficult because few studies with good long-term followup have evaluated local recurrence, disease-free survival, and overall survival after ablation. This and other limitations make it difficult to draw meaningful conclusions.
In this short review, we describe two new liver-specific contrast agents for MRI that are in clinical development. The main differences among the liver-specific contrast agents available at present are also discussed briefly.
A 58-year-old man presented with symptoms of abdominal pain of several weeks duration. At physical evaluation, jaundice and ascites were present. In addition, a palpable mass was identified in the right upper quadrant. Surgical resection was performed.
A 68-year-old man developed hepatocellular carcinoma associated with chronic alcohol abuse and cirrhosis. He began to receive sorafenib (400 mg twice daily) as management for advanced disease. About 8 weeks after drug initiation, the patient noted the rapid onset of two nodules nearly identical in appearance.
A 57-year-old woman developed a solitary nodular hepatocellular carcinoma. After about 3 months on sorafenib, following pulmonary metastases, the patient experienced the explosive onset of a moderately pruritic cutaneous eruption.
Five Steps to Improving Patient Access Judy Capko, May 21, 2013 Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.